Court Overseeing Federal Testosterone Treatment Lawsuits Issues New Case Management Order
The federal litigation underway in Illinois includes hundred of testosterone lawsuits filed on behalf of men who suffered heart attacks, strokes, and other life-threatening cardiovascular events, allegedly due to their use of low testosterone therapy.
Under the December 13, 2014 Case Management Order the Court has established procedures to facilitate the coordination of testosterone lawsuits pending in the federal proceeding with those that have been filed in state courts. Among other things, the Order directs the Plaintiffs Steering Committee for the federal litigation to coordinate discovery with state court proceedings to the furthest extent possible. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
The Ahearne Law Firm, PLLC is a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who were allegedly harmed by AndroGel and other testosterone treatments. Men who have allegedly suffered heart attacks, strokes and other life-threatening cardiovascular events due to their use of low testosterone therapy should contact The Ahearne Law Firm, PLLC for a free consolation and case evaluation.
Testosterone Treatment Litigation
According to court documents, more than 270 testosterone treatment lawsuits are now pending in the federal litigation underway in the Northern District of Illinois. All of the claims allege that this class of medications is associated with an increased risk of heart attack, stroke and other serious cardiovascular side effects. Among other things, the complaints claim that sales of testosterone replacement products were driven by deceptive marketing tactics that induced many healthy men to use the drugs in the absence of a true medical need. Plaintiffs further allege that the manufacturers of low testosterone therapies failed to warn doctors and patients about their potential risks, and concealed those dangers from the public.
Testosterone lawsuits began mounting in U.S. courts following the Food & Drug Administrations (FDA) January announcement that it was evaluating the cardiovascular risks associated with low testosterone therapy. Since then, a panel of FDA advisors recommended that the drugs labels be revised to make clear they have not been shown to lessen low libido, fatigue, muscle loss and other age-related symptoms. They also recommended that the manufacturers of testosterone replacement therapies be required to conduct studies of their cardiovascular side effects.
Men who allegedly suffered heart attacks, stroke, deep vein thrombosis, pulmonary embolism or other serious cardiovascular problems due to their use of prescription testosterone therapies may be entitled to join this growing litigation.